Amendments to the Specification:

Please replace the paragraph beginning on page 1, line 2, with the following rewritten paragraph:

This applications is a ~~continuation~~divisional of application Serial No. 09/428,082, filed October 22, 1999, which claims the benefit of United States Provisional application 60/105,371, filed October 23, 1998, which are incorporated by reference herein.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A composition of matter of the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

and multimers thereof, wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c\text{-}P^1$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently randomized EPO-mimetic antagonist peptide sequences;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1 and wherein "peptide" refers to molecules 2 to 40 amino acid and wherein neither X1 nor X2 is a native protein.

2. (original) The composition of matter of Claim 1 of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

3. (original) The composition of matter of Claim 1 of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1.$$

4. (original) The composition of matter of Claim 1 of the formula

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$$

5. (original) The composition of matter of Claim 1 wherein F^1 is an IgG Fc domain.

6. (original) The composition of matter of Claim 1 wherein F^1 is an IgG1 Fc domain.

7. (original) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

8. (canceled).

9. (canceled).

10. (canceled).

11. (canceled).

12. (canceled).

13. (previously presented) The composition of matter of Claim 1 wherein the EPO mimetic peptide sequence is selected from Table 5.

14. (previously presented) The composition of matter of Claim 1 wherein F^1 comprises the sequence of SEQ ID NO: 2.

15. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 83, 84, 85, 124, 419, 420, 421, and 41.

16. (previously presented) The composition of matter of Claim 1 comprising a sequence selected from SEQ ID NOS: 339 and 340.

Claims 17 - 51 (canceled).

52. (new) A DNA encoding a composition of matter of Claim 1.

53. (new) An expression vector comprising the DNA of Claim 52.

54. (new) A host cell comprising the expression vector of Claim 53.

55. (new) The cell of Claim 54, wherein the cell is an E. coli cell.

56. (new) A process for preparing a EPO-mimetic antagonist peptide, which comprises

a) selecting at least one randomized EPO-mimetic antagonist peptide; and

b) preparing a EPO-mimetic antagonist peptide comprising at least one Fc domain covalently linked to at least one amino acid sequence of the selected peptide or peptides.

57. (new) The process of Claim 56, wherein the peptide is selected in a process comprising screening of a phage display library, an E. coli display library, a ribosomal library, or a chemical peptide library.

58. (new) The process of Claim 56 wherein the Fc domain is an IgG Fc domain.

59. (new) The process of Claim 56, wherein the vehicle is an IgG1 Fc domain.

60. (new) The process of Claim 56, wherein the vehicle comprises the sequence of SEQ ID NO: 2.

61. (new) The process of Claim 56, wherein the compound prepared is of the formula

$$(X^1)_a\text{-}F^1\text{-}(X^2)_b$$

and multimers thereof,wherein:

F^1 is an Fc domain;

X^1 and X^2 are each independently selected from $-(L^1)_c\text{-}P^1$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2$, $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3$, and $-(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2\text{-}(L^3)_e\text{-}P^3\text{-}(L^4)_f\text{-}P^4$

P^1, P^2, P^3, and P^4 are each independently sequences of pharmacologically active peptides;

L^1, L^2, L^3, and L^4 are each independently linkers; and

a, b, c, d, e, and f are each independently 0 or 1, provided that at least one of a and b is 1.

62. (new) The process of Claim 56, wherein the compound prepared is of the formulae

$$X^1\text{-}F^1$$

or

$$F^1\text{-}X^2.$$

63. (new) The process of Claim 56, wherein the compound prepared is of the formulae

$$F^1\text{-}(L^1)_c\text{-}P^1$$

or

$$F^1\text{-}(L^1)_c\text{-}P^1\text{-}(L^2)_d\text{-}P^2.$$

64. (new) The process of Claim 56, wherein F^1 is an IgG Fc domain.

65. (new) The process of Claim 56, wherein F^1 is an IgG1 Fc domain.

66. (new) The process of Claim 56, wherein F^1 comprises the sequence of SEQ ID NO: 2.